About the Editors

Scott WaldmanScott Waldman, MD, PhD, FCP
Dr. Waldman is the Samuel MV Hamilton Endowed Professor of Medicine, the Chair of the Department of Pharmacology and Experimental Therapeutics, the Director of the Division of Clinical Pharmacology, and the Director of the Developmental Therapeutics program of the Kimmel Cancer Center at Thomas Jefferson University. He is a past president of ASCPT and served on its Board of Directors. Dr. Waldman holds an MD from Stanford University and a PhD from Thomas Jefferson University. He is a leading clinician investigator whose extensive research spans the pharmacology spectrum from molecular biology of signal transduction to novel diagnostics and therapeutics for cancer. His studies have resulted in more than 130 publications and have produced more than 45 awarded patents and patent applications worldwide.

Andre Terzic Andre Terzic, MD, PhD
Dr. Terzic is a Professor of Medicine and Molecular Pharmacology and Experimental Therapeutics at the Mayo Clinic College of Medicine. He is a Mayo Foundation Endowed Career Scientist and program co-Director for the Postgraduate Cardiovascular Fellowship Program at the Mayo Graduate School of Medicine. Dr. Terzic received his MD from the School of Medicine at the University of Belgrade and continued his education at the University of Illinois, receiving a PhD in pharmacology. He is a past president of ASCPT and is active in many roles at the Mayo Clinic including Vice-Chairman of the Department of Cardiovascular Research and Director of the Cardiovascular Research Laboratory and the NIH Cardiovascular Training Program in Cardiovasology. Dr. Terzic is a widely published author and educator in the field of pharmacology.

Arthur J. Atkinson Arthur J. Atkinson, MD
Dr. Atkinson received his Bachelor of Arts degree in chemistry from Harvard College and his MD from Cornell University Medical College. After initiating the clinical pharmacology program at Northwestern University Medical School, Dr. Atkinson pursued such notable positions as Corporate Vice President for Clinical Development and Medical Affairs at the Upjohn Company and Adjunct Professor in the Center for Drug Development Science at Georgetown University. He was later appointed Senior Advisor in Clinical Pharmacology to the Director of the NIH Clinical Center. Dr. Atkinson is a Master of the American College of Physicians and has served as president for the American Board of Clinical Pharmacology and ASCPT. He has contributed to many professional societies as an editorial board member and is extensively published in the field of pharmacology.

Raymond J. Hohl Raymond J. Hohl, MD, PhD
Dr. Hohl is the Holden Family Chair, Professor of Internal Medicine and Pharmacology, Associate Chair in the Department of Internal Medicine, Associate Director for Translational Research in the Holden Comprehensive Cancer Center. He received his Ph.D. in Pharmacology from Rush University. He is a Diplomate of the American Board of Internal Medicine, a Fellow at the American College of Physicians and has been recognized with such honors as the PMA Faculty Development Award in Clinical Pharmacology and the Laureate Award from the Iowa Chapter of the American College of Physicians. Dr. Hohl earned his MD at Rush Medical College. His clinical research interests focus on the evaluation of the potential role for pharmacologic inhibitors of this biosynthetic pathway in the treatment of various hematologic malignancies and solid tumors.

Peter K. Honig Peter K. Honig, MD, MPH
Dr. Honig is the Executive Vice President of Worldwide Regulatory Affairs and Product Safety for Merck Research Laboratories. After receiving his baccalaureate, medical and public health degrees from Columbia University, he joined the Food and Drug Administration as a medical review officer in the Division of Pulmonary and Allergy Drug Products. Dr. Honig is a Fellow of the American College of Physicians and a past president of ASCPT.

Shiew-Mei Huang Shiew-Mei Huang, PhD
Dr. Huang is the Deputy Office Director for Science in the Office of Clinical Pharmacology at the Food and Drug Administration's Center for Drug Evaluation and Research. She is an American Association of Pharmaceutical Scientists Fellow and Diplomate of the American Board of Clinical Pharmacology. Dr. Huang oversees several external research projects on drug metabolism, pharmacogenetics and clinical QT evaluations. She has published more than 90 peer-reviewed articles and book chapters with a focus on clinical pharmacology, drug metabolism and biopharmaceutics.

Gregory L. Kearns Gregory L. Kearns, PharmD, PhD
Dr. Kearns is Chairman of Pediatric Medical Research at the Children's Mercy Hospital and the Marion Merrell Dow/Missouri Chair in Pediatric Medical Research at the University of Missouri-Kansas City School of Medicine. He received his Bachelor of Science degree from the St. Louis College of Pharmacy and his PharmD from the University of Cincinnati. Dr. Kearns continued his education, earning a PhD in Medicine and Clinical Pharmacology from Erasmus University. Dr. Kearns has received the Distinguished Investigator Award from the American College of Clinical Pharmacology and is a recipient of the Roy Patterson Distinguished Lectureship from the American Academy of Allergy, Asthma and Clinical Immunology. He is widely published and is a past president of ASCPT.

Richard L. Lalonde Richard L. Lalonde, PharmD
Dr. Lalonde is the Executive Director of the Clinical Pharmacokinetics and Pharmacodynamics Department at Pfizer Global Research and Development. He has significantly contributed to ASCPT as Chair of the Pharmacokinetics and Drug Metabolism Section and serves on the Coordinating Committee on Scientific Sections with responsibilities for Pharmacometrics and Biostatistics and Gastrointestinal, Endocrine and Metabolic Diseases sections.

Micheline Piquette-Miller Micheline Piquette-Miller, PhD
Dr. Piquette-Miller is an Associate Professor and Director of the Division of Pharmaceutical Sciences at the University of Toronto. She received her BSc and PhD in Pharmaceutical Sciences from the University of Alberta and continued her postdoctoral research studies at the Department of Biopharmaceutical and Molecular Pharmacology at the University of California, San Francisco. Dr. Piquette-Miller is the President of the Canadian Society of Clinical Pharmacology and has served on the Board of Directors and Chair of the Pharmacogenetics and Molecular Pharmacology Section for ASCPT. She has been the recipient of numerous awards and honors for her research in the areas of drug transport and multidrug resistance including the 2006 Leon I. Goldberg Young Investigator Award from ASCPT.